These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 28664852)

  • 21. Glucocorticoids and mepolizumab in eosinophilic asthma.
    Iikura M; Hojo M; Sugiyama H
    N Engl J Med; 2014 Dec; 371(25):2433-4. PubMed ID: 25517713
    [No Abstract]   [Full Text] [Related]  

  • 22. Glucocorticoids and mepolizumab in eosinophilic asthma.
    Lindsay JT; Heaney L
    N Engl J Med; 2014 Dec; 371(25):2433. PubMed ID: 25517712
    [No Abstract]   [Full Text] [Related]  

  • 23. Mepolizumab-responsive Kimura disease.
    Kinoshita M; Ogawa Y; Onaka M; Shimada S; Kawamura T
    J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2928-2930. PubMed ID: 33684634
    [No Abstract]   [Full Text] [Related]  

  • 24. Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase.
    Caminati M; Crisafulli E; Lunardi C; Micheletto C; Festi G; Maule M; Giollo A; Orsolini G; Senna G
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1386-1388. PubMed ID: 33011303
    [No Abstract]   [Full Text] [Related]  

  • 25. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.
    Katz LE; Gleich GJ; Hartley BF; Yancey SW; Ortega HG
    Ann Am Thorac Soc; 2014 May; 11(4):531-6. PubMed ID: 24606022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mepolizumab-based therapy in asthma: an update.
    Walsh GM
    Curr Opin Allergy Clin Immunol; 2015 Aug; 15(4):392-6. PubMed ID: 26110690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarkers for severe eosinophilic asthma.
    Yancey SW; Keene ON; Albers FC; Ortega H; Bates S; Bleecker ER; Pavord I
    J Allergy Clin Immunol; 2017 Dec; 140(6):1509-1518. PubMed ID: 29221581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on new biologics for intractable eosinophilic asthma: impact of reslizumab.
    Sahota J; Robinson DS
    Drug Des Devel Ther; 2018; 12():1173-1181. PubMed ID: 29780238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
    Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
    Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mepolizumab in the treatment of severe eosinophilic asthma.
    Fainardi V; Pisi G; Chetta A
    Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reappraisal of the clinical effect of mepolizumab - Authors' reply.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A
    Lancet Respir Med; 2017 Jun; 5(6):e21. PubMed ID: 28664853
    [No Abstract]   [Full Text] [Related]  

  • 32. Pediatric eosinophilic bronchiolitis successfully treated with mepolizumab.
    Arceri T; Kurland G; Reyes-Múgica M; Larkin A
    J Allergy Clin Immunol Pract; 2022 Mar; 10(3):874-875. PubMed ID: 34775119
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
    Matera MG; Calzetta L; Rinaldi B; Cazzola M
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):1007-1013. PubMed ID: 28737051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison.
    Cockle SM; Stynes G; Gunsoy NB; Parks D; Alfonso-Cristancho R; Wex J; Bradford ES; Albers FC; Willson J
    Respir Med; 2017 Feb; 123():140-148. PubMed ID: 28137490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
    Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
    Shimoda T; Odajima H; Okamasa A; Kawase M; Komatsubara M; Mayer B; Yancey S; Ortega H
    Allergol Int; 2017 Jul; 66(3):445-451. PubMed ID: 28110896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mepolizumab (Nucala) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jan; 58(1486):11-2. PubMed ID: 26761344
    [No Abstract]   [Full Text] [Related]  

  • 39. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma.
    Yancey SW; Ortega HG; Keene ON; Mayer B; Gunsoy NB; Brightling CE; Bleecker ER; Haldar P; Pavord ID
    J Allergy Clin Immunol; 2017 Apr; 139(4):1167-1175.e2. PubMed ID: 27726946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overlapping Effects of New Monoclonal Antibodies for Severe Asthma.
    Domingo C
    Drugs; 2017 Oct; 77(16):1769-1787. PubMed ID: 28948572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.